UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________ FORM 6-K ________________________________ Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: August 9, 2024 Commission File Number: 001-39307 ________________________________ | --- | |-----------------------------------------------------------------------------------------| | | | | | (Exact Name of Registrant as Specified in its Chart ...

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $186 million MHRA and Health Canada approved CARVYKTI® in earlier lines of treatment for adult patients with relapsed and lenalidomide-refractory multiple myeloma CARVYKTI® demonstrates positive overall survival results in second interim analysis of CARTITUDE4 study Cash and cash equivalents, deposits and short-term investments of $1.3 billion, as of June 30, 2024, which Legend Biotech believes will provide financial runway in ...

For the six-months ended June 30, 2024, Legend Biotech expects to record an adjusted net loss for the period of approximately $94.7 million to $109.7 million. See "Use of Non-IFRS Financial Measures" below for a reconciliation of net loss to adjusted net loss for the first six months of the year. Use of Non-IFRS Financial Measures The following table provides a reconciliation of Legend Biotech's net loss for the six-month period to adjusted net loss for the six-month period: About Legend Biotech Learn more ...

SOMERSET, N.J., July 26, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced preliminary, unaudited financial results for the six-months ended June 30, 2024. Use of Non-IFRS Financial Measures Adjusted net loss for the year is a non-IFRS financial measure. Adjusted net loss for the year has limitations in that it does not reflect all expense items that affect Legend Biotech's results. Learn more at https://legendbiotech.com/ a ...

強生目前將血液腫瘤管線作為其重點推進的領域之一，而傳奇生物的Carvykti則是 其繼伊布替尼之後最重磅的一款藥物。自獲FDA批准上市以來，Carvykti保持著良 好的上升勢頭。強生對Carvykti的前景非常看好，預計其銷售峰值能夠達到50億美 元+。2018年公司和楊森協議共同開發Carvykti，其中在中國區傳奇承擔70%的開 發、生產與商業化成本，並保留或承擔70%的稅前損益。而在中國之外地區，雙方 平等分擔開發、生產和商業化成本和損益。18年Q1從楊森收到了3.5億美元的預付 款，同時有資格獲得楊森追加13.5億美元里程碑式付款。但在後續協議中，由於雙 方同意對臨床開發計畫進行修改，導致決定不按原計劃進行某些試驗，在13.5億美 元中可能無法獲得約2.8億美元的資金。 楊森已於18年12月支付第一里程碑付款2500萬美元，2019年9月楊森支付第二里程 碑式付款2500萬美元，用於CARTUDE-1臨床試驗中收到特定數量患者的反應資料， 顯示ORR至少為50%。在CARTUDE-1臨床試驗中對指定數量的患者進行給藥後，楊森 支付第三和第四里程碑付款各3000萬美金。20年12月由於完成與美國食品藥 ...

The article further claimed that LEGN hired investment banking firm Centerview Partners to assist its board of directors in reviewing this takeover offer. The article did not provide information on whether this interest could lead to a potential sale. Legend is yet to confirm these reports. In April, the FDA granted label expansion to the J&J-partnered therapy to treat adult patients with MM who have received at least one prior line of therapy, including a proteasome inhibitor (PI) and an immunomodulatory a ...

SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results. A replay version of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentation section approximately two hours after the call concludes. During the w ...

分析师 - 丁政宁 | 李柳晓 ◎ 我们认为,关于cilta-cel商业化潜力的市场预期差有望逐步修复。相比 同靶点竞品,cilta-cel在关键适应症中的临床数据更强、先发优势明显, 近期2L MM获批显著扩大患者人群,短期内有望推动销售快速放量。 ◎ 公司目标2025年底产能达10,000剂，足以支持40亿美元以上的年销售 额。公司还通过和CMO合作解决短期产能紧缺问题。我们认为后续产 能释放将是重要的销售增长驱动力和股价催化剂。 2024年6月18日 交银国际研究 首次覆盖 股份资料 52周高位 (美元) 76.50 52周低位 (美元) 40.01 市值 (百万美元) 7,564.62 日均成交量 (百万) 0.00 年初至今变化 (%) (31.03) 200天平均价 (美元) 54.70 资料来源：公司资料，交银国际预测 Cilta-cel 海外商业化和适应症扩展进程顺利，预计销售峰值达 73 亿美 元。自 2022 年首次获批以来，cilta-cel 已经在美国、欧洲和日本商业化， 用于晚期复发/难治多发性骨髓瘤（MM）的末线治疗。2024 年 4 月，基 于 CARTITUDE-4 试验的优异 ...

1 May 13, 2024 First Quarter 2024 Financial Results & Corporate Update This presentation is for investor relations purposes only - Not for product promotional purposes Forward-looking Statements This presentation has been prepared by Legend Biotech Corporation ("Legend Biotech" or the "Company") solely for information purpose and does not contain all relevant information relating to the Company. The safety and efficacy of the agents and/or uses under investigation discussed in this presentation have not bee ...

Thank you. And our next question coming from the line of Leonid Timashev with RBC Capital Markets. Your line is open. Joining me on today's call are Ying Huang, the company's Chief Executive Officer; and Lori Macomber, the company's Chief Financial Officer. Following their prepared remarks, we will open up the call for a Q&A. We have Guowei Fang, Chief Scientific Officer, and Steve Gavel, Head of Commercial Development for the US and Europe, joining the Q&A session. Good morning, Kostas. Thanks for the ques ...